Fourier Transform of Videokeratography Data: Clinical Usefulness in Moderate and Frome Fruste Keratoconus
Launched by DEMOCRITUS UNIVERSITY OF THRACE · Nov 25, 2015
Trial Information
Current as of April 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosis of keratoconus KC in the fellow eye according to the Amsler-Krumleich criteria (FFKG)
- • KISA index between 60 and 100% in the FFK eye (FFKG)
- • lack of any KC-related findings / signs in the slit-lamp biomicroscopy (FFKG)
- • uneventful ophthalmologic history (CG)
- • no indications of corneal pathology in slit-lamp biomicroscopy and Placido \*disk-based videokeratography (CG)
- • KISA index value less than 60% (CG)
- • diagnosed and classified for moderate keratoconus according to the Amsler-Krumeich classification system (KCG)
- Exclusion Criteria:
- * for all study groups:
- • previous incisional eye surgery
- • corneal scars and opacities
- • history of herpetic keratitis, severe eye dryness
- • pregnancy or nursing
- • current corneal infection
- • glaucoma
- • suspicion for glaucoma
- • IOP lowering treatment
- • underlying autoimmune disease
About Democritus University Of Thrace
Democritus University of Thrace is a leading academic institution in Greece, renowned for its commitment to advancing health sciences through innovative research and clinical trials. The university's research initiatives are driven by a multidisciplinary approach, fostering collaboration among experts in medicine, pharmacology, and biotechnology. With a focus on improving patient outcomes and contributing to the global body of medical knowledge, Democritus University of Thrace actively sponsors clinical trials that address critical health challenges, ensuring adherence to the highest ethical and scientific standards. Through its dedication to education and research, the university plays a pivotal role in shaping the future of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Alexandroupolis, Evros, Greece
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials